A Study to Learn About Sickle Cell Disease In Adult Patients
Completed
Conditions studied: Sickle Cell Disease
In brief
The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a treatment. SCD is a type of condition when there are fewer red blood cells to carry oxygen around the body. This disease can be passed on from parent to child and may cause pain, infections and damage to organs. This study is seeking participants who: * are confirmed with SCD * are on a stable regimen of disease changing treatment or have not received any disease changing treatment before the start of the study and do not plan any changes in their treatment during the 6-month study observation period For 6 months, participants will be asked to complete a daily electronic diary to report on their experience in the past 24 hours with sickle cell pain crisis (if they got any treatment and what medications they took), worst pain, worst tiredness, and their ability to perform usual physical activities. We will compare the experiences of people who are taking SCD-modifying therapy to those that are not taking a SCD-modifying therapy.
Key facts
- Study ID
- NCT05407805
- Run by
- Pfizer
- People needed
- 98
- Starts
- 2022-02-10
- Expected to finish
- 2024-06-24
- Last updated by the study team
- 2026-06-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Foundation for Sickle Cell Disease Research — Hollywood, Florida, United States
- Mid-Atlantic Permanente Medical Group Largo Medical Center — Upper Marlboro, Maryland, United States
- Sanguine Biosciences, Inc. — Waltham, Massachusetts, United States
- Cohen Children's Medical Center — New Hyde Park, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.